SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-22-000032
Filing Date
2022-05-11
Accepted
2022-05-11 16:08:07
Documents
40
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q awh-20220331x10q.htm   iXBRL 10-Q 1526381
2 EX-31.1 awh-20220331xex31_1.htm EX-31.1 15344
3 EX-31.2 awh-20220331xex31_2.htm EX-31.2 16819
4 EX-32.1 awh-20220331xex32_1.htm EX-32.1 12552
  Complete submission text file 0000926617-22-000032.txt   4796517

Data Files

Seq Description Document Type Size
5 EX-101.SCH awh-20220331.xsd EX-101.SCH 24534
6 EX-101.CAL awh-20220331_cal.xml EX-101.CAL 41145
7 EX-101.DEF awh-20220331_def.xml EX-101.DEF 101401
8 EX-101.LAB awh-20220331_lab.xml EX-101.LAB 239005
9 EX-101.PRE awh-20220331_pre.xml EX-101.PRE 203011
34 EXTRACTED XBRL INSTANCE DOCUMENT awh-20220331x10q_htm.xml XML 746157
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
Aspira Women's Health Inc. (Filer) CIK: 0000926617 (see all company filings)

IRS No.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 22913762
SIC: 2835 In Vitro & In Vivo Diagnostic Substances